[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-markers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-markers":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,76,108,132,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100615034","phase-4-colchicines-effect-on-inflammatory-markers-100615034",false,"NCT07287345","Colchicine's Effect on Inflammatory Markers","Adjunctive Colchicine's Effect on Inflammatory Markers and Corresponding New-Onset Atrial Fibrillation Rates Post Coronary Artery Bypass Graft Procedure: A Pilot Study","Inclusion Criteria:\n\n* Age 18 years and older\n* Coronary artery bypass graft (CABG) planned procedure\n\nExclusion Criteria:\n\n* History of atrial fibrillation\n* Off-pump CABG procedure\n* Current treatment with colchicine for any cause\n* Hypersensitivity to colchicine (as indicated by rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever)\n* Emergency cardiac surgery\n* Extracorporeal Membrane Oxygenation (ECMO) pre- or post-cardiac surgery\n* Heart transplant patients\n* Left ventricular assist device (LVAD) patients\n* Serum creatinine \\>2.0 mg\u002FdL\n* Preoperative elevated CK or known myopathy\n* Severe liver disease or elevation of serum transaminases (\\>1.5 times the upper limit of 40 units\u002Fliter)\n* Chronic intestinal disease or blood dyscrasia\n* Unable to speak English\n* Pregnancy or lactation in women","ALL","18 Years","99 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study wants to see if the medicine colchicine can help lower inflammation and reduce the chance of developing an irregular heartbeat (atrial fibrillation) after heart bypass surgery. Adults having coronary artery bypass surgery (CABG) can join. Participants will be randomly placed into one of two groups: one group will receive colchicine along with usual care, and the other will receive a placebo (a look-alike capsule with no medicine) along with usual care. Everyone will take a study capsule, and neither the patients nor the study team will know which capsule is being given. Everyone in the study will take study capsule, and neither the patients nor the study team will know who is receiving colchicine or placebo. Blood samples and health information will be collected before surgery; at 24, 48, 72, and 96 hours after surgery; and again at 10 days after surgery or at hospital discharge, whichever comes first. The investigators will look at inflammation marker levels, whether atrial fibrillation happens, and any side effects. This small study will help to generate effect size estimates and safety data that will help plan a larger study in the future.",[27,28,29,30,31],"Colchicine","Inflammation in Cardiac Surgery","Post Operative Atrial Fibrillation","Inflammatory Markers","Colchicine Adverse Reaction","RECRUITING","2026-06-23",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":36},"2026-01-16",{"date":40,"type":21},"2026-12-30",{"name":42,"class":43},"Ayesha Ather","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100584967","fiber-smoothie-supplement-100584967","NCT06896240","Fiber Smoothie Supplement","The Impact of a Daily Whole Food Plant-based Smoothie Utilization 2 Weeks Prior to Revision Total Knee Replacement Surgery on Inflammation and Post-operative Pain.","Inclusion:\n\n* Scheduled for revision TKA at HSS with participating surgeons; not as a result of infection or trauma and all components (tibial and femoral) needing replacement\n* Age between 40 and 80\n* Diagnosed with osteoarthritis\n* Diagnosed with 2+ modifiable chronic lifestyle diseases: Type 2 DM, CVD (such as CAD, heart disease, stroke, HTN), stress, anxiety, depression, ADHD, metabolic syndrome, certain types of cancer (such as breast, colorectal, lung, prostate), Alzheimer's disease, vascular cognitive impairment, CKD, RA, asthma, chronic pain conditions (such as chronic back pain and osteoarthritis), fibromyalgia, migraines, COPD (Steiber 2011, Grant 2014)\n* ASA Class 1 ('normal' healthy patient) or 2 (patient with mild systemic disease and no functional limitations; the diseases the patient has are well controlled)\n* Ability to understand written and spoken English\n* Willing to complete entire pre-operative and post-operative work up in NYC, main campus site\n* Willing to follow a 2-week smoothie supplement, including willingness to purchase ingredients and have access to a blender for preparation\n\nExclusion:\n\n* Age \\>80 years or \\\u003C40 years\n* Revision due to infection or trauma\n* ASA class 3 (patient with severe systemic disease that results in functional limitations) or 4 (patient with severe systemic disease that is a constant threat to life)\n* Not interested or unable to provide informed consent\n* Unstable weight (\\>5kg weight change in the past 3 months, documented in Epic) or currently on weight loss drugs such as GLP-1 agonists (Prasad et al., Cardiovasc Diabetol 2022; empagliflozin CRP studies.)\n* Active infection, flare-up of seasonal allergies, or physical trauma (all can alter CRP)\n* Medication changes the month leading up to surgery\n* Specifically medications altering inflammation: Statins (Ridker 2008), steroids (Boumpas et al., Ann Intern Med 1993; glucocorticoid cytokine modulation research.), DMARDS\u002Fbiologics\u002Fimmunosuppressants (Clinical rheumatology guidelines, biologic RCTs (e.g., TNF inhibitors, IL-6 inhibitors), Colchicine (Tardif et al., N Engl J Med 2019; colchicine cardiovascular inflammation studies.), hormone replacement therapies (Ridker et al., JAMA 1999; OCs and CRP meta-analyses.), new psychiatric medications (Miller \\& Raison, Nat Rev Immunol 2016; psychotropic-inflammation associations.)\n* BMI \\>40 kg\u002Fm2\n* Food intolerance\u002Fallergy\u002Fsensitivity to ingredients suggested for smoothies\n* History of IBD (and IBD medication)\n* History of bariatric surgery\n* History of cancer\n* History of thyroid disease\n* History of or current drug abuse\n* Pregnancy\n* Current smoker\n* Any patient with an electronic cardiac implant","40 Years","80 Years",{"count":20,"type":21},[56],"NA","This study aims to assess the feasibility of a 2-week dietary whole-food smoothie intervention and compare outcomes between two groups: patients that integrated a daily whole food plant-based smoothie into their diet for two weeks prior to surgery, and a control group of revision TKA patients that made no nutritional changes to their diet prior to surgery. The main research questions are:\n\n1. Among patients planned for elective TKA revision surgery, what is the feasibility of a 2-week dietary intervention implemented 2 weeks prior to surgery? \\[Outcomes will be compliance, noted barriers and\u002For facilitators, satisfaction with diet\\]\n2. Determine if the implementation of a daily whole food plant- based smoothie dietary supplement 2 weeks prior to TKA revision surgery will reduce inflammation -measured in plasma levels of IL-6 and CRP- at POD0, POD1, POD2, POD3, and 6 Weeks Post-operative as compared to 1) baseline (prior to dietary intervention initiation) and 2) control patients who did not make changes in their diet prior to surgery.\n3. Determine if the implementation of a daily whole food plant-based smoothie dietary supplement 2 weeks prior to TKA revision surgery will result in quantifiable changes in the gut microbiome composition -measured via fecal samples- as compared to control patients who did not make changes in their diet prior to surgery.\n4. Determine if the implementation of a daily whole food plant- based smoothie dietary supplement 2 weeks prior to TKA revision surgery will result in improved immediate postoperative pain -measured through numeric rating scale (NRS) pain scores- and opioid use -measured in morphine milligram equivalents (MME)- as compared to control patients.\n5. Compare patient satisfaction and adoption of nutritional behavioral changes in patients implementing a whole food plant-based smoothie 2 weeks prior to TKA revision surgery to patients undergoing the same surgery but did not me pre-surgery dietary changes.\n\nThe researcher's primary outcome is measuring feasibility and patient compliance with smoothie consumption. Secondarily, the investigators are interested in measuring if the preoperative smoothie can alter the gut microbiome and decrease systemic inflammation, leading to lowered post-operative pain and opioid use.",[59,30,60],"Total Knee Arthroplasty Revision","Gut Microbiota",[62,63,64,65],"TKA Revision","Inflammation","Diet","Gut Microbiome","NOT_YET_RECRUITING","2026-04-23",{"date":69,"type":36},"2026-04-28",{"date":71,"type":21},"2026-05",{"date":73,"type":21},"2028-01-01",{"name":75,"class":43},"Hospital for Special Surgery, New York",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100620861","platelet-changes-in-type-2-diabetes-100620861","NCT07363122","Platelet Changes in Type 2 Diabetes","Platelet Indices Changes in Type 2 Diabetes Mellitus and Their Relationship With Inflammatory Markers","Inclusion Criteria:\n\n* Adults aged 30-70 years.\n* Diagnosed T2DM for at least 1 year.\n* Fasting blood glucose ≥126 mg\u002FdL and\u002For HbA1c ≥ 6.5%\n\nExclusion Criteria:\n\n* Type 1 Diabetes Mellitus\n* Acute infection, chronic inflammatory disease\n* Malignancy.\n* Current use of anti-platelet or anti-inflammatory medications\n* Chronic liver, renal, or hematologic disease\n* Recent major surgery or trauma (within 3 months)",true,"30 Years","70 Years",{"count":87,"type":21},200,"OBSERVATIONAL","This study examines changes in platelet indices in people with type 2 diabetes compared to healthy people. It checks if these changes relate to inflammation markers (like hs-CRP) and blood sugar control. Participants get routine blood tests during one clinic visit at Assiut University Hospitals. No treatments or extra procedures are involved.",[91,92,30],"Platelet Indices","Type 2 Diabetes",[94,95,96,97,98],"Platelets","Platelet indices","T2DM","Type 2 Diabetes Mellitus","inflammatory markers","2026-01-15",{"date":101,"type":36},"2026-01-23",{"date":103,"type":21},"2026-02",{"date":105,"type":21},"2027-03",{"name":107,"class":43},"Assiut University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":44},"100465161","non-nutritive-sweetener-consumption-and-glucose-homeostasis-in-older-adults-with-prediabetes-100465161","NCT05337098","Non-Nutritive Sweetener Consumption and Glucose Homeostasis in Older Adults With Prediabetes","Non-Nutritive Sweetener Consumption (Aspartame and Sucralose) and Glucose Homeostasis in Older Adults With Prediabetes","Inclusion Criteria:\n\n* Age 40+ years\n* Prediabetic (fasting glucose concentration of 100-125 mg\u002FdL, 2-hour oral glucose tolerance test glucose concentration of 140-199 mg\u002FdL, or a HbA1c value of 5.7% to 6.4%)\n* Weight stable for previous 6 months (±2 kg)\n* BMI \\\u003C40 kg\u002Fm2\n* Sedentary to recreationally active\n* No plans to gain\u002Flose weight or change physical activity level\n* Willing to pick up food daily and consume foods provided for an 8-week period\n* Verbal and written informed consent\n* Approval by Medical Director\n* Consume less than one serving of non-nutritive sweetener per week\n\nExclusion Criteria:\n\n* BMI \\>40 kg\u002Fm2\n* Diabetes or diabetes medication\n* Antibiotic, prebiotic or prebiotic use in prior 3 months\n* Uncontrolled hypertension (blood pressure (BP) \\> 159\u002F99 mmHg)\n* Diagnosed inflammatory bowel disease\n* Past or current heart diseases, stroke, respiratory disease, endocrine or metabolic disease, or hematological-oncological disease\n* Vegetarian or vegan\n* Pregnant or plans to become pregnant\n* Breastfeeding\n* Food allergies or aversions, Phenylketonuria (PKU)\n* Estrogen or testosterone usage",{"count":116,"type":21},30,[56],"Animal and observational research in humans suggest that specific types of non-nutritive sweeteners (NNS) may impair glycemic control. However, whether NNS consumption impacts glucose homeostasis in middle-aged\u002Folder adults with prediabetes is unknown, and potential mechanisms by which this could occur have yet to be identified. The overall objective of this R21 proposal is to establish proof-of-concept for alterations in glucose homeostasis following intake of sucralose, but not aspartame, in middle-aged\u002Folder adults with prediabetes compared to a eucaloric diet with no NNS.",[120,121,122,30],"Continuous Glucose Monitoring","Oral Glucose Tolerance","Insulin Sensitivity","2025-12-03",{"date":125,"type":36},"2025-12-04",{"date":127,"type":36},"2023-04-18",{"date":129,"type":21},"2026-02-28",{"name":131,"class":43},"Virginia Polytechnic Institute and State University",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":140,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":44},"100599223","walnuts-as-an-infant-solid-food-for-health-100599223","NCT07081698","Walnuts as an Infant Solid Food for Health","Walnut as a First Food During Complementary Feeding on Gut Microbiota and Immunity Development in Breastfed Infants","WISH","Inclusion Criteria:\n\n* Full term: gestational age ≥ 37 weeks\n* Generally healthy without conditions that would affect normal growth\n* No significant consumption of complementary food (e.g., no more than 1 oz of solid foods per week)\n* Exclusively breastfed (\\\u003C 2 weeks of cumulative formula exposure)\n\nExclusion Criteria:\n\n* Adults unable to consent\n* Pregnant women\n* Prisoners","5 Months",{"count":142,"type":21},90,[56],"The objective is to investigate the effect of walnuts on gut microbiota, inflammatory markers, atopic dermatitis status, and indices of allergy outcomes in breastfed infants during early complementary feeding.\n\nThe three primary aims include:\n\nAim 1: Evaluate the effect of walnut consumption on gut microbiota structure and function, inflammation, atopic dermatitis, and allergy outcomes.\n\nAim 2: Evaluate the impact of walnut consumption on infant growth trajectories and risk of overweight.\n\nAim 3 (exploratory): Identify walnut-specific food signatures that are associated with gut microbiota and immunity biomarkers using a novel nutri-metabolomics technique.",[146,30,147],"Gut -Microbiota","Infant Development",[149,150,151,152,153,154],"Walnut","Microbiome","Infant","Pediatric","Nutrition","Health","2025-07-16",{"date":157,"type":36},"2025-07-23",{"date":159,"type":36},"2025-05-18",{"date":161,"type":21},"2027-12-31",{"name":163,"class":43},"Colorado State University",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":170,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100481811","evaluation-of-inflammatory-markers-in-ph-negative-myeloproliferative-neoplasms-impact-on-outcome-and-response-to-therapy-multicenter-retro-prospective-observational-study-the-infla-me-inflammation-in-myeloproliferative-disease-study-100481811","NCT05553873","Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of diagnosis of MPN Ph negative\n* Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000)\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* Life expectancy of less than 6 months\n* Accelerated phase myelofibrosis or MPN with signs of leukemic evolution",{"count":171,"type":21},500,"This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated \u002F blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification",[174,30],"Myeloproliferative Disease","2023-12-29",{"date":177,"type":36},"2024-01-02",{"date":179,"type":36},"2022-09-08",{"date":181,"type":21},"2026-12",{"name":183,"class":43},"University of Milano Bicocca",11]